Skip to main content

Animations

MJFF Publications

6491 - 6500 of 9034 Results
Title
Year
  • Year
  • 2018
  • 2018
  • 2018
  • 2020
  • 2013
  • 2018
  • 2018
  • 2018
  • 2016
  • 2017
  • Summary Details
    OPEN
    Title: Synergistic neuroprotection by coffee components eicosanoyl-5-hydroxytryptamide and caffeine in models of Parkinson's disease and DLB
    Journal Name: Proceedings of the National Academy of Sciences
    Publisher: National Academy of Sciences
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1073/pnas.1813365115
    Citation Count: 92
  • Summary Details
    OPEN
    Title: Minimal Clinically Important Difference for UPDRS‐III in Daily Practice
    Journal Name: Movement Disorders Clinical Practice
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/mdc3.12632
    Citation Count: 63
  • Summary Details
    OPEN
    Title: Dual role of USP 30 in controlling basal pexophagy and mitophagy
    Journal Name: The EMBO Reports
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.15252/embr.201745595
    Citation Count: 163
  • Analysis of Heterozygous PRKN Variants and Copy‐Number Variations in Parkinson's Disease
    2020
    Summary Details
    RESTRICTED
    Title: Analysis of Heterozygous PRKN Variants and Copy‐Number Variations in Parkinson's Disease
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1002/mds.28299
    Citation Count: 49
  • Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia
    2013
    Summary Details
    RESTRICTED
    Title: Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia
    Journal Name: Neuroscience Research
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.neures.2013.10.002
    Citation Count: 47
  • Summary Details
    OPEN
    Title: Inhaling xenon ameliorates l‐dopa‐induced dyskinesia in experimental parkinsonism
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1002/mds.27404
    Citation Count: 16
  • Summary Details
    OPEN
    Title: Neuromodulation targets pathological not physiological beta bursts during gait in Parkinson's disease
    Journal Name: Neurobiology of Disease
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.nbd.2018.09.004
    Citation Count: 148
  • Summary Details
    OPEN
    Title: Stimulation-induced reversed plus-minus syndrome: Insights into eyelid physiology
    Journal Name: Brain Stimulation
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.brs.2018.04.010
    Citation Count: 3
  • Summary Details
    OPEN
    Title: Atrophy and structural covariance of the cholinergic basal forebrain in primary progressive aphasia
    Journal Name: Cortex
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.cortex.2016.07.004
    Citation Count: 23
  • Summary Details
    OPEN
    Title: Thalamic cholinergic innervation makes a specific bottom-up contribution to signal detection: Evidence from Parkinson’s disease patients with defined cholinergic losses
    Journal Name: NeuroImage
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.neuroimage.2017.02.006
    Citation Count: 50
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.